drugset / Trial / NCT05093907
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).
Timeline
- Start
- 2021-08-31
- Primary completion
- 2026-11-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVOTACICLIB | Small molecule | — | Oral |
| Background | Capecitabine | Small molecule | — | Oral |